Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tae Jun Song

Showing results (191-200 of 218) with videos related to

Pageof 22
Sort By:
Journal of Gastroenterology and Hepatology|January 30, 2023
Comparison of the long-term outcomes between proximal and distal IgG4-related sclerosing cholangitis: A multicenter cohort studySung Hyun Cho, Tae Jun Song, Jin-Seok Park, et al.
Cancer Research and Treatment|November 10, 2020
Adjuvant Chemotherapy for Resected Ampulla of Vater Carcinoma: Retrospective Analysis of 646 PatientsJwa Hoon Kim, Jae Ho Jeong, Baek-Yeol Ryoo, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|February 23, 2024
Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline resectable and locally advanced pancreatic adenocarcinomaHyunseok Yoon, Yeokyeong Shin, Baek-Yeol Ryoo, et al.
Cancers|March 10, 2022
Stereotactic Body Radiation Therapy versus Concurrent Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Propensity Score-Matched AnalysisYoung Seob Shin, Hee Hyun Park, Jin-Hong Park, et al.
Cancers|March 1, 2019
Clinical Outcomes of Conversion Surgery after Neoadjuvant Chemotherapy in Patients with Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer: A Single-Center, Retrospective AnalysisChanghoon Yoo, Sang Hyun Shin, Kyu-Pyo Kim, et al.
Therapeutic Advances in Medical Oncology|May 16, 2022
Real-world outcomes of adjuvant gemcitabine <i>versus</i> gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinomaSora Kang, Changhoon Yoo, So Heun Lee, et al.
Cancer Research and Treatment|March 14, 2023
Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOXSo Heun Lee, Dae Wook Hwang, Changhoon Yoo, et al.
The International Journal of Biological Markers|June 8, 2018
Prognostic implications of hepatitis B virus infection in intrahepatic cholangiocarcinoma treated with first-line gemcitabine plus cisplatinHeejung Chae, Hyungwoo Cho, Changhoon Yoo, et al.
Investigational New Drugs|April 5, 2018
Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysisJihoon Kang, Inhwan Hwang, Changhoon Yoo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 3, 2017
Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic AdenocarcinomaKoji Shindo, Jun Yu, Masaya Suenaga, et al.
Pageof 22

Showing results (191-200 of 218) with videos related to

Sort By:
Pageof 22
Journal of Gastroenterology and Hepatology|January 30, 2023
Comparison of the long-term outcomes between proximal and distal IgG4-related sclerosing cholangitis: A multicenter cohort studySung Hyun Cho, Tae Jun Song, Jin-Seok Park, et al.
Cancer Research and Treatment|November 10, 2020
Adjuvant Chemotherapy for Resected Ampulla of Vater Carcinoma: Retrospective Analysis of 646 PatientsJwa Hoon Kim, Jae Ho Jeong, Baek-Yeol Ryoo, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|February 23, 2024
Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline resectable and locally advanced pancreatic adenocarcinomaHyunseok Yoon, Yeokyeong Shin, Baek-Yeol Ryoo, et al.
Cancers|March 10, 2022
Stereotactic Body Radiation Therapy versus Concurrent Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Propensity Score-Matched AnalysisYoung Seob Shin, Hee Hyun Park, Jin-Hong Park, et al.
Cancers|March 1, 2019
Clinical Outcomes of Conversion Surgery after Neoadjuvant Chemotherapy in Patients with Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer: A Single-Center, Retrospective AnalysisChanghoon Yoo, Sang Hyun Shin, Kyu-Pyo Kim, et al.
Therapeutic Advances in Medical Oncology|May 16, 2022
Real-world outcomes of adjuvant gemcitabine <i>versus</i> gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinomaSora Kang, Changhoon Yoo, So Heun Lee, et al.
Cancer Research and Treatment|March 14, 2023
Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOXSo Heun Lee, Dae Wook Hwang, Changhoon Yoo, et al.
The International Journal of Biological Markers|June 8, 2018
Prognostic implications of hepatitis B virus infection in intrahepatic cholangiocarcinoma treated with first-line gemcitabine plus cisplatinHeejung Chae, Hyungwoo Cho, Changhoon Yoo, et al.
Investigational New Drugs|April 5, 2018
Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysisJihoon Kang, Inhwan Hwang, Changhoon Yoo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 3, 2017
Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic AdenocarcinomaKoji Shindo, Jun Yu, Masaya Suenaga, et al.
Pageof 22